by CN Bio. | Mar 1, 2021 | Press releases
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...
by CN Bio. | Feb 17, 2021 | OOC Blog
How Mimicking Blood Flow Makes Organ-on-a-Chip Technology Even More Life-like With every beat of your heart, blood rushes through your body. Some floods your arteries traveling from the lungs back to the heart. Some squeezes almost single-file, one frisbee-shaped...
by CN Bio. | Jan 27, 2021 | NASH
Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled since the 1970s. Increased obesity has triggered a wave of serious associated health conditions, notably cardiovascular...
by CN Bio. | Jan 11, 2021 | Press releases
FDA publication demonstrates advantages of PhysioMimix™ in drug safety and metabolism applications, over standard techniques Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator Characterizing the...
by CN Bio. | Jan 11, 2021 | OOC Blog
How a Partnership between the FDA and Organ-on-a-Chip Developers Has the Potential to Fast-track Drug Development From a small discovery in a research lab to a capsule on a pharmacist’s shelf – the path of drug development is a long one. Whilst scientists discover or...
